WO2008106213A1 - Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. - Google Patents
Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. Download PDFInfo
- Publication number
- WO2008106213A1 WO2008106213A1 PCT/US2008/002680 US2008002680W WO2008106213A1 WO 2008106213 A1 WO2008106213 A1 WO 2008106213A1 US 2008002680 W US2008002680 W US 2008002680W WO 2008106213 A1 WO2008106213 A1 WO 2008106213A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ditpa
- mammal
- administered
- dosage
- document
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- This application relates to 3,5-diiodothyropropionic acid (DITPA) compositions and methods of use of such compositions for stimulating weight loss, lowering triglyceride levels, and/or treating metabolic syndrome.
- DITPA 3,5-diiodothyropropionic acid
- metabolic syndrome a cluster of medical conditions characterized by abdominal obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, high blood pressure, and elevated fasting blood glucose. Having three or more traits of metabolic syndrome significantly increases the risk of dying from coronary heart disease or cardiovascular disease. It has also been reported that patients with even one or two metabolic syndrome traits, or those with metabolic syndrome but without diabetes also were at increased risk for death from coronary heart disease or cardiovascular disease.
- Obesity and atherosclerosis have a major impact on morbidity and mortality in the United States and many other countries. Elevated cholesterol, particularly low-density lipoprotein (LDL) cholesterol, is a major risk factor for atherosclerosis. Thyroid hormone replacement in hypothyroid individuals reduces total cholesterol and LDL-cholesterol. An excess of thyroid hormone in thyrotoxicosis causes weight loss. The weight loss consists not only of fat but also muscle mass and even myopathy can be observed.
- LDL low-density lipoprotein
- Adipose tissue is the largest storehouse of energy in the body (in the form of triglycerides) and typically makes up 15-20% or more of the body weight in men and 20-25% more of the body weight in women.
- U.S. Pat. Nos. 4,451,465, 4,772,631, 4,977,148 and 4,999,377 disclose compounds possessing thermogenic properties at dosages causing few or no deleterious side-effects, such as cardiac stimulation.
- Goglia and Lanni in W02005009433 describe the use of a breakdown product of thyroid hormone (3,5,-diiodothyronine) as a regulator of lipid metabolism to stimulate burning of fatty acid in mitochondria.
- the invention provides methods and/or kits for stimulating weight loss, lowering triglyceride and/or lipoprotein levels, and/or treating metabolic syndrome, comprising administering a therapeutically effective amount of DITPA to an individual in need thereof, such as an overweight mammal.
- the overweight mammal does not have congestive heart failure.
- the invention provides a method for stimulating weight loss in an overweight mammal, comprising administering a therapeutically effective amount of DITPA to the mammal.
- the invention provides a method for lowering triglyceride levels in an overweight mammal, comprising administering a therapeutically effective amount of DITPA to the mammal.
- the invention provides a method for lowering lipoprotein levels in an overweight mammal, comprising administering a therapeutically effective amount of DITPA to the mammal.
- low density lipoprotein (LDL) levels are decreased.
- high density lipoprotein (HDL) levels are decreased.
- the mammal has metabolic syndrome.
- the mammal is a human. In some embodiments, the human has a body mass index greater than 25. In some embodiments, the human does not have congestive heart failure.
- DITPA is administered as a liquid preparation, a solid preparation, a capsule preparation, and an implant preparation.
- the formulation may also comprise a pharmaceutically acceptable carrier. In some embodiments, the formulation further comprises a stabilizer, an excipient, a solubilizer, an antioxidant, a pain-alleviating agent, and/or an isotonic agent. In various embodiments, DITPA is administered orally, transdermally, by parenteral injection, by parenteral intravenous injection, by implantation, or directly to the pulmonary system of the mammal.
- DITPA is administered to the mammal at a dosage of about 0.6 to about 5.1 mg DITPA per kg per day. In some embodiments, DITPA is administered to the mammal at a dosage of about 1.875 to about 3.75 mg per kg per day. In some embodiments, DITPA is administered in combination with a lipid lowering therapeutic agent.
- a method for stimulating weight loss in an overweight mammal comprising administering to said mammal a therapeutically effective amount of DITPA, wherein the mammal does not have congestive heart failure.
- said mammal is a human.
- said human has a body mass index over 25.
- said mammal has metabolic syndrome.
- said DITPA is administered as a formulation selected from the group consisting of: a liquid preparation, a solid preparation, a capsule preparation, and an implant preparation, wherein said formulation further comprises a pharmaceutically acceptable carrier.
- said DITPA is administered as a capsule.
- said formulation further comprises at least one of a stabilizer, an excipient, a solubilizer, an antioxidant, a pain- alleviating agent, and an isotonic agent.
- said DITPA is administered orally, transdermally, by parenteral injection, by parenteral intravenous injection, by implantation, or directly to the pulmonary system of said mammal.
- said DITPA is administered orally.
- said DITPA is administered to said mammal at a dosage comprising about 0.1 to about 10.0 milligrams per kilogram per day.
- said DITPA is administered to said mammal at a dosage comprising about 0.6 to about 5.1 milligrams per kilogram per day.
- said DITPA is administered to said mammal at a dosage comprising about 1.875 to about 3.75 milligrams per kilogram per day. In some embodiments, said DITPA is administered to said mammal in combination with a lipid lowering therapeutic agent.
- a method for lowering triglyceride levels in an overweight mammal comprising administering to said mammal a therapeutically effective amount of DITPA, wherein the mammal does not have congestive heart failure.
- said mammal is a human.
- said human has a body mass index over 25.
- said mammal has metabolic syndrome.
- said DITPA is administered as a formulation selected from the group consisting of: a liquid preparation, a solid preparation, a capsule preparation, and an implant preparation, wherein said formulation further comprises a pharmaceutically acceptable carrier.
- said DITPA is administered as a capsule, hi some embodiments, said formulation further comprises at least one of a stabilizer, an excipient, a solubilizer, an antioxidant, a pain- alleviating agent, and an isotonic agent.
- said DITPA is administered orally, transdermally, by parenteral injection, by parenteral intravenous injection, by implantation, or directly to the pulmonary system of said mammal.
- said DITPA is administered orally.
- said DITPA is administered to said mammal at a dosage comprising about 0.1 to about 10.0 milligrams per kilogram per day.
- said DITPA is administered to said mammal at a dosage comprising about 0.6 to about 5.1 milligrams per kilogram per day. In some embodiments, said DITPA is administered to said mammal at a dosage comprising about 1.875 to about 3.75 milligrams per kilogram per day. In some embodiments, said DITPA is administered to said mammal in combination with a lipid lowering therapeutic agent.
- DITPA 3,5-diiodothyropropionic acid
- said mammal is a human.
- said human has a body mass index over 25.
- said DITPA is administered as a formulation selected from the group consisting of: a liquid preparation, a solid preparation, a capsule preparation, and an implant preparation, wherein said formulation further comprises a pharmaceutically acceptable carrier.
- said DITPA is administered as a capsule.
- said formulation further comprises at least one of a stabilizer, an excipient, a solubilizer, an antioxidant, a pain-alleviating agent, and an isotonic agent.
- said DITPA is administered orally, transdermally, by parenteral injection, by parenteral intravenous injection, by implantation, or directly to the pulmonary system of said mammal.
- said DITPA is administered orally.
- said DITPA is administered to said mammal at a dosage comprising about 0.1 to about 10.0 milligrams per kilogram per day.
- said DITPA is administered to said mammal at a dosage comprising about 0.6 to about 5.1 milligrams per kilogram per day.
- said DITPA is administered to said mammal at a dosage comprising about 1.875 to about 3.75 milligrams per kilogram per day. In some embodiments, said DITPA is administered to said mammal in combination with a lipid lowering therapeutic agent.
- kits for use in any of the methods described herein comprising at least one unit dose of DITPA, and optionally comprising instructions for use in methods for stimulating weight loss, lowering triglyceride levels, and/or treating metabolic syndrome.
- DITPA for use in a method of treatment comprising stimulating weight loss in an overweight mammal, wherein the overweight mammal does not have congestive heart failure.
- DITPA formulations thereof, as described herein are also intended for use in a method of treatment comprising stimulating weight loss in an overweight mammal, wherein the overweight mammal does not have congestive heart failure, and in accordance with the methods, as described herein, unless clearly dictated otherwise by context or specifically noted.
- DITPA in another aspect of the invention is provided the use of DITPA in the manufacture of a medicament for use in stimulating weight loss in an overweight mammal, wherein the overweight mammal does not have congestive heart failure.
- the formulations thereof, as described herein are also intended for use in the manufacture of a medicament for use in stimulating weight loss in an overweight mammal, wherein the overweight mammal does not have congestive heart failure, and in accordance with the methods, as described herein, unless clearly dictated otherwise by context or specifically noted.
- DITPA for use in a method of treatment comprising lowering triglyercide levels in an overweight mammal in need thereof, wherein the overweight mammal does not have congestive heart failure.
- the DITPA formulations thereof, as described herein are also intended for use in a method of treatment comprising lowering triglyercide levels in an overweight mammal in need thereof, wherein the overweight mammal does not have congestive heart failure, and in accordance with the methods, as described herein, unless clearly dictated otherwise by context or specifically noted.
- DITPA in another aspect of the invention is provided the use of DITPA in the manufacture of a medicament for use in lowering triglyceride levels in an overweight mammal in need thereof, wherein the overweight mammal does not have congestive heart failure.
- the formulations thereof, as described herein are also intended for use in the manufacture of a medicament for use in lowering triglyceride levels in an overweight mammal in need thereof, wherein the overweight mammal does not have congestive heart failure, and in accordance with the methods, as described herein, unless clearly dictated otherwise by context or specifically noted.
- DITPA for use in a method of treatment of metabolic syndrome in an overweight mammal in need thereof, wherein the overweight mammal does not have congestive heart failure.
- the DITPA formulations thereof, as described herein are also intended for use in a method of treatment of metabolic syndrome in an overweight mammal in need thereof, wherein the overweight mammal does not have congestive heart failure, and in accordance with the methods, as described herein, unless clearly dictated otherwise by context or specifically noted.
- DITPA in another aspect of the invention is provided the use of DITPA in the manufacture of a medicament for use in treating metabolic syndrome in an overweight mammal in need thereof, wherein the overweight mammal does not have congestive heart failure.
- the formulations thereof, as described herein are also intended for use in the manufacture of a medicament for use in treating metabolic syndrome in an overweight mammal in need thereof, wherein the overweight mammal does not have congestive heart failure, and in accordance with the methods, as described herein, unless clearly dictated otherwise by context or specifically noted.
- DITPA formulations as described herein are intended for use in the methods of treatment as described herein and may be incorporated in the kits described herein.
- the invention provides methods, compositions, and kits for stimulating weight loss and/or lowering triglyceride and/or lipoprotein levels using DITPA.
- a therapeutically effective amount of DITPA is administered to an overweight individual to effect weight loss, and/or lowering of triglyceride and/or lipoprotein levels, and/or treatment of metabolic syndrome.
- the overweight individual is a mammal that does not have congestive heart failure.
- treatment is defined as therapeutically beneficial administration of a pharmaceutical composition of the present invention to an individual.
- One outcome of the treatment may be stimulating weight loss of an individual (such as a mammal).
- Another outcome of the treatment may be lowering triglyceride levels in the body of an individual (such as a mammal).
- Another outcome of the treatment may be reduction or elimination of one or more symptoms of metabolic syndrome in an individual (such as a mammal), for example, stimulating weight loss, or lowering triglyceride levels.
- administering is defined as providing a pharmaceutical composition of the present invention to a mammal (e.g, a human) in need of treatment.
- therapeutically effective amount refers to the amount of DITPA that will render a desired therapeutic outcome (e.g., stimulating weight loss or lowering triglyceride levels).
- a therapeutically effective amount may be administered in one or more doses.
- DITPA is generally administered in a pharmaceutically acceptable carrier.
- pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
- pharmaceutically acceptable refers to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
- the "Body Mass Index (BMI)" is calculated as kilogram of body weight per height in meters squared (kg/m 2 ). Generally, a human with a BMI in the range of 25- 30 kg/m 2 is considered overweight, with obesity at a BMI greater than 30 kg/m 2 .
- BMI-based definition of overweight may be modified to reflect changes in understanding of the condition or practices in the field. Such changes to the BMI- based definition of overweight are contemplated herein. A skilled artisan would also understand that other methods of measurement may be used to define overweight. Such methods are also contemplated in the present invention.
- weight refers to an individual having more body fat than is typical or required for the normal functioning of the body.
- triglyceride is defined as a chemical having a structure of:
- R 11 COOH can be all different, all the same, or only two the same.
- the term "metabolic syndrome” is defined as in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP-III). E.S. Ford et al., JAMA, vol. 287(3), Jan. 16, 2002, pp356-359.
- the metabolic syndrome is characterized by a group of metabolic risk factors, including abdominal obesity, hypertriglyceridemia, low HDL cholesterol, high blood pressure, and high fasting plasma glucose.
- a human is defined to have metabolic syndrome when the human has 3 or more aforementioned symptoms.
- the term "congestive heart failure” is defined to mean a syndrome in a mammal due to any structural or functional cardiovascular disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood throughout the body. This can result from, for example, narrowed arteries that supply blood to the heart muscle (coronary artery disease); past heart attack, or myocardial infarction, with scar tissue that interferes with the heart muscle's normal work; high blood pressure; heart valve disease, due to past rheumatic fever or other causes; primary disease of the heart muscle itself (cardiomyopathy); heart defects present at birth (congenital heart defects); or infection of the heart valves and/or heart muscle itself (endocarditis and/or myocarditis).
- narrowed arteries that supply blood to the heart muscle (coronary artery disease); past heart attack, or myocardial infarction, with scar tissue that interferes with the heart muscle's normal work; high blood pressure; heart valve disease, due to past rheumatic fever or other causes
- Methods are provided for administration of DITPA to an overweight individual in need of treatment for stimulating weight loss, lowering triglyceride levels, lowering lipoprotein levels, or treating metabolic syndrome. Methods include administration of one or more unit doses of DITPA in a therapeutically effective amount.
- DITPA is generally administered in a pharmaceutically acceptable carrier.
- the individual to whom DITPA is administered does not have congestive heart failure.
- the individual has a Body Mass Index greater than 25.
- a therapeutically effective dose may be administered as a single dose or in multiple doses per day, with the total daily dosage comprising a total dosage of about 0.1 to about 10 milligrams DITPA per kilogram per day.
- DITPA is administered at a dosage of about 0.6 to about 5.1 milligrams per kilogram per day.
- DITPA is administered at a dosage of about 1.875 to about 3.75 milligrams per kilogram per day.
- methods of the invention comprise administering any of about 0.1, 0.2, 0.3, 0.4, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 milligrams DITPA per kilogram per day.
- about 0.1 mg to about 0.2 mg, about 0.2 mg to about 0.5 mg, about 0.5 mg to about 1.0 mg, about 1.0 mg to about 2.0 mg, about 2.0 mg to about 4.0 mg, about 4.0 mg to about 6.0 mg, about 6.0 mg to about 8.0 mg, or about 8.0 mg to about 10.0 mg DITPA is administered per kilogram per day.
- a total dose of any of about 4.5, 10, 20, 30, 45, 50, 75, 90, 125, 150, 180, 200, 225, 250, 270, 300, 325, 360, 400, or 450 mg of DITPA is administered per day.
- about 45 mg to about 100 mg, about 100 mg to about 200 mg, about 200 mg to about 300 mg, about 300 mg to about 400 mg, or about 400 mg to about 450 mg DITPA is administered per day.
- a therapeutically effective dosage of DITPA is administered in conjunction with one or more additional therapeutic agents, such as one or more lipid lowering agents, either concurrently or sequentially with respect to administration of DITPA.
- weight loss comprises a reduction of any of about 2% to about 15% body weight, or lowering of Body Mass Index by about 4% to about 12%.
- reduction in triglyceride level comprises a reduction of any of about 10, 15, 20, 25, 30, 35, or 40% triglyceride.
- treatment of metabolic syndrome comprises amelioration or elimination of one or more symptoms, such as improvement in exercise tolerance or decreased shortness of breath.
- DITPA has been previously described, and preparation may be achieved in accordance with methods that are well known in the art. See, e.g., U.S. Pat. No. 6,534,676.
- DITPA is administered in a pharmaceutical composition that comprises a unit dose of DITPA and a pharmaceutically acceptable carrier.
- administration may be oral or parenteral (e.g., intravenous, subcutaneous, intramuscular), transdermal, transmucosal (including buccal, nasal, rectal, sublingual, and vaginal), by inhalation, or via an implanted reservoir in a dosage form.
- the pharmaceutical formulation may be a solid, semi-solid, or liquid, such as, for example, a tablet, a capsule, a caplet, a liquid, a suspension, an emulsion, a gel, a suppository, granules, pellets, beads, a powder, or the like, preferably in unit dosage form suitable for single administration of a precise dosage.
- suitable pharmaceutical compositions and dosage forms may be prepared using conventional methods known to those in the field of pharmaceutical formulation and described in the pertinent texts and literature, e.g., in Remington: The Science and Practice of Pharmacy (Easton, PA: Mack Publishing Co., 1995).
- oral dosage forms are generally preferred, and include tablets, capsules, caplets, solutions, suspensions, and syrups, and may also comprise a plurality of granules, beads, powders, or pellets that may or may not be encapsulated.
- Preferred oral dosage forms are tablets and capsules.
- DITPA capsules for oral administration comprise about 45 or about 90 mg of DITPA.
- the capsules comprise about 45 mg of DITPA, about 149 mg microcrystalline cellulose (e.g.,Avicel PH 302), and about 2 mg magnesium stearate.
- the capsules comprise about 90 mg of DITPA, about 125 mg microcrystalline cellulose (e.g.,Avicel PH 302), and about 4 mg magnesium stearate.
- capsules for oral administration comprise about 25 to about 360 mg DITPA.
- capsules for oral administration comprise any of about 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or 120, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, or 360 mg DITPA.
- Tablets may be manufactured using standard tablet processing procedures and equipment. Direct compression and granulation techniques are preferred.
- tablets will generally contain inactive, pharmaceutically acceptable carrier materials such as binders, lubricants, disintegrants, fillers, stabilizers, surfactants, coloring agents, and the like. Binders are used to impart cohesive qualities to a tablet, and thus ensure that the tablet remains intact.
- Suitable binder materials include, but are not limited to, starch (including corn starch and pregelatinized starch), gelatin, sugars (including sucrose, glucose, dextrose, and lactose), polyethylene glycol, waxes, and natural and synthetic gums, e.g., acacia sodium alginate, polyvinylpyrrolidone, cellulosic polymers (including hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, microcrystalline cellulose, ethyl cellulose, hydroxyethyl cellulose, and the like), and Veegum.
- Lubricants are used to facilitate tablet manufacture, promoting powder flow and preventing particle capping (i.e., particle breakage) when pressure is relieved.
- Useful lubricants are magnesium stearate, calcium stearate, and stearic acid.
- Disintegrants are used to facilitate disintegration of the tablet, and are generally starches, clays, celluloses, algins, gums, or crosslinked polymers.
- Fillers include, for example, materials such as silicon dioxide, titanium dioxide, alumina, talc, kaolin, powdered cellulose, and microcrystalline cellulose, as well as soluble materials such as mannitol, urea, sucrose, lactose, dextrose, sodium chloride, and sorbitol.
- Stabilizers as well known in the art, are used to inhibit or retard drug decomposition reactions that include, by way of example, oxidative reactions.
- the active agent-containing composition may be encapsulated in the form of a liquid or solid (including particulates such as granules, beads, powders, or pellets).
- Suitable capsules may be either hard or soft, and are generally made of gelatin, starch, or a cellulosic material, with gelatin capsules preferred.
- Two-piece hard gelatin capsules are preferably sealed, such as with gelatin bands or the like. See, for example, Remington: The Science and Practice of Pharmacy, cited supra, which describes materials and methods for preparing encapsulated pharmaceuticals.
- DITPA capsules are gelatin capsules containing about 45 milligrams or about 90 milligrams of DITPA, microcrystalline cellulose and magnesium stearate.
- Oral dosage forms may, if desired, be formulated so as to provide for gradual, sustained release of the active agent over an extended time period.
- sustained release dosage forms are formulated by dispersing the active agent within a matrix of a gradually hydrolyzable material such as a hydrophilic polymer, or by coating a solid, drug-containing dosage form with such a material.
- Hydrophilic polymers useful for providing a sustained release coating or matrix include, by way of example: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, acrylic acid alkyl esters, methacrylic acid alkyl esters, and the like, e.g.
- Preparations according to this invention for parenteral administration include sterile aqueous and nonaqueous solutions, suspensions, and emulsions.
- Injectable aqueous solutions contain the active agent in water-soluble form.
- nonaqueous solvents or vehicles include fatty oils, such as olive oil and corn oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, low molecular weight alcohols such as propylene glycol, synthetic hydrophilic polymers such as polyethylene glycol, liposomes, and the like.
- Parenteral formulations may also contain adjuvants such as solubilizers, preservatives, wetting agents, emulsifiers, dispersants, and stabilizers, and aqueous suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and dextran.
- Injectable formulations are rendered sterile by incorporation of a sterilizing agent, filtration through a bacteria-retaining filter, irradiation, or heat. They can also be manufactured using a sterile injectable medium.
- the active agent may also be in dried, e.g., lyophilized, form that may be rehydrated with a suitable vehicle immediately prior to administration via injection.
- DITPA may also be administered through the skin using conventional transdermal drug delivery systems, wherein the active agent is contained within a laminated structure that serves as a drug delivery device to be affixed to the skin.
- the drug composition is contained in a layer, or "reservoir,” underlying an upper backing layer.
- the laminated structure may contain a single reservoir, or it may contain multiple reservoirs.
- the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery.
- the drug-containing reservoir and skin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form.
- Transdermal drug delivery systems may in addition contain a skin permeation enhancer.
- DITPA may also be administered directly to the pulmonary system of mammals and human, for example, in the form of inhalation or insufflation.
- a DITPA solution may be delivered in the form of an aerosol spray presentation from pressurized packs or nebulizer, with the use of suitable propellants such as carbon dioxide or other suitable gasses.
- DITPA may also be formulated as a depot preparation for controlled release of the active agent, preferably sustained release over an extended time period.
- sustained release dosage forms are generally administered by implantation (e.g., subcutaneously or intramuscularly or by intramuscular injection).
- compositions will generally be administered orally, parenterally, transdermal Iy, directly to the pulmonary system, or via an implanted depot, other modes of administration are suitable as well.
- administration may be rectal or vaginal, preferably using a suppository that contains, in addition to the active agent, excipients such as a suppository wax.
- Formulations for nasal or sublingual administration are also prepared with standard excipients well known in the art.
- the pharmaceutical compositions of the invention may also be formulated for inhalation, e.g., as a solution in saline, as a dry powder, or as an aerosol. Combination therapy
- DITPA is administered in combination with a single or a plurality of lipid lowering agents.
- Administration of one or more lipid lowering agents may be either concurrent or sequential with respect to administration of DITPA.
- DITPA and one or more lipid lowering agents may be administered in the same or different formulations.
- lipid lowering agent is defined as a drug that can be used to lower plasma lipid, e.g., cholesterol, triglyceride, levels and/or raise high-density lipoprotein levels.
- lipid lowering agents include, but are not limited to, HMG CoA reductase inhibitors commonly referred to as "statins," bile acid sequestrants, fibric acid derivatives, nicotinic acid (NiacinTM), probucol (LorelcoTM), and inhibitors of cholesterol absorption such as ezetimibe (ZetiaTM).
- HMG CoA reductase inhibitors commonly referred to as "statins”
- bile acid sequestrants include, but are not limited to, bile acid sequestrants, fibric acid derivatives, nicotinic acid (NiacinTM), probucol (LorelcoTM), and inhibitors of cholesterol absorption such as ezetimibe (ZetiaTM).
- HMG CoA reductase inhibitors include, but are not limited to, atorvastatin (LipitorTM), simvastatin (ZocorTM), fluvastatin (LescolTM), lovastatin (MevacorTM), rosuvastatin (CrestorTM), and pravastatin (PravocholTM) or the like.
- atorvastatin LipitorTM
- simvastatin ZocorTM
- fluvastatin LescolTM
- lovastatin lovastatin
- CrestorTM rosuvastatin
- pravastatin Pieric acid sequestrants
- bile acid sequestrants include, but are not limited to, cholestyramine (CholybarTM, QuestranTM), and colestipol (ColestidTM).
- fibric acid derivatives include, but are not limited to, gemfibrozil (LopidTM), clof ⁇ brate (Atromid-STM), and fenofibrate (TricorTM).
- the lipid lowering agents are co-administered with DITPA.
- the lipid lowering agents are administered separately, but within a treatment regime that includes administration of DITPA.
- the invention provides pharmaceutical compositions for use in any of the methods described herein, comprising DITPA as a therapeutically active ingredient.
- a pharmaceutical compositions for use in the methods of the invention generally comprises a unit dose of DITPA and a pharmaceutically acceptable carrier.
- a pharmaceutical composition further comprises one or a plurality of second therapeutic ingredients, such as one or a plurality of lipid lowering agents.
- the pharmaceutical composition comprises about 25 to about 360 mg of DITPA.
- the pharmaceutical composition comprises any of about 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 1 10, 115, or 120, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, or 360 mg of DITPA. Kits
- Kits are provided for use in methods of the invention for stimulating weight loss, lowering triglyceride levels, or treatment of metabolic syndrome.
- the kits include a pharmaceutical composition for use in a method of the invention, for example, including at least one unit dose of DITPA, and instructions providing information to a health care provider or patient regarding such usage. Instructions may be provided in printed form or in the form of an electronic medium such as a floppy disc, CD, or DVD, or in the form of a website address where such instructions may be obtained.
- Suitable packaging refers to a solid matrix or material customarily used in a system and capable of holding within fixed limits a DITPA- containing composition suitable for administration to an individual.
- materials include glass and plastic (e.g., polyethylene, polypropylene, and polycarbonate) bottles, vials, paper, plastic, and plastic-foil laminated envelopes and the like. If e-beam sterilization techniques are employed, the packaging should have sufficiently low density to permit sterilization of the contents.
- kits can contain dosage forms, e.g. , separately sealed, and/or individually removable unit dosage forms packaged in a container, wherein each unit dosage form comprises a pharmaceutical composition containing (i) a unit dosage of a DITPA- containing composition as described herein, and (ii) a pharmaceutically acceptable carrier, wherein the unit dosage is effective to provide a therapeutically effective amount.
- Kits may further comprise instructions describing administration of the dosage forms in a manner effective to stimulate weight loss, to lower triglyceride levels, and/or to treat metabolic syndrome.
- kits may also optionally include equipment for administration of DITPA, such as, for example, syringes or equipment for intravenous administration, and/or a sterile solution, e.g., a diluent such as 5% dextrose, for preparing a dry powder (e.g., lyophilized) composition for administration.
- equipment for administration of DITPA such as, for example, syringes or equipment for intravenous administration
- a sterile solution e.g., a diluent such as 5% dextrose
- Kits of the invention may include, in addition to DITPA, one or a plurality of second therapeutic ingredients, such as one or a plurality of lipid lowering agents, for use with DITPA as described in the methods above.
- Example 2 A Randomized, Double-Blind, Placebo-Controlled Study of DITPA for the Reduction of Weight and Improvement in Metabolic Abnormalities in Obese Adults
- the objectives of this study are to evaluate the efficacy of DITPA in addition to a hypocaloric diet for weight reduction in obese adult humans. Secondary objectives are to evaluate the effects of DITPA on serum triglycerides, LDL cholesterol, waist circumference, fat free mass, resting energy expenditure, markers of insulin sensitivity and bone turnover, and to evaluate the safety of DITPA in this patient population.
- the study consists of a Screening Phase, a Pre-Randomization Phase that consists of dietary counseling plus a 2-week Placebo Run-in Period, and a 16- week Treatment Phase. Patients are seen 28 days after the End of Treatment Visit. The total duration on study is approximately 24 weeks. Study Population
- the study population consists of patients with a BMI > 30 kg/m 2 who are interested in weight loss.
- a BMI > 30 kg/m 2 who are interested in weight loss.
- at least 50% of the targeted study population has hypertriglyceridemia (> 150 mg/dL).
- the study population does not include patients with congestive heart failure.
- the primary endpoint is weight change from baseline to week 16.
- Secondary endpoints include: percent change in weight from baseline to week 16; proportion of subjects achieving weight loss greater than or equal to 5%; proportion of subjects achieving weight loss greater than or equal to 10%; percent change in serum triglyceride levels from baseline to week 16; percent change in total cholesterol levels from baseline to week 16; percent change in LDL cholesterol levels from baseline to week 16; change in waist circumference from baseline to week 16; change in fat mass by dual energy X-ray absorptiometry (DXA) from baseline to week 16; change in fat free mass by DXA from baseline to week 16; change in percentage of body fat by DXA from baseline to week 16; change in resting energy expenditure from baseline to week 16; change in nocturnal heart rate from baseline to week 16; change in QUICKI index [l/logi 0 (insulin) + logio(glucose)] from baseline to week 12; and change in markers of bone formation and bone resorption from baseline to week 12.
- DXA dual energy X-ray absorpti
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2009009171A MX2009009171A (en) | 2007-02-27 | 2008-02-27 | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. |
AU2008219585A AU2008219585A1 (en) | 2007-02-27 | 2008-02-27 | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. |
US12/596,818 US8399518B2 (en) | 2007-02-27 | 2008-02-27 | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome |
CA002679402A CA2679402A1 (en) | 2007-02-27 | 2008-02-27 | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90399407P | 2007-02-27 | 2007-02-27 | |
US60/903,994 | 2007-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008106213A1 true WO2008106213A1 (en) | 2008-09-04 |
Family
ID=39721556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/002680 WO2008106213A1 (en) | 2007-02-27 | 2008-02-27 | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. |
Country Status (5)
Country | Link |
---|---|
US (1) | US8399518B2 (en) |
AU (1) | AU2008219585A1 (en) |
CA (1) | CA2679402A1 (en) |
MX (1) | MX2009009171A (en) |
WO (1) | WO2008106213A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012171065A1 (en) * | 2011-06-17 | 2012-12-20 | Esra Ogru | Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa). |
WO2024015764A1 (en) * | 2022-07-11 | 2024-01-18 | PriZm, LLC | 3,5-diiodothyropropionic acid compositions and methods of use thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202005949UA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
SG11202005947RA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6951844B2 (en) * | 2001-12-07 | 2005-10-04 | Bristol Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
WO2005097102A2 (en) * | 2004-04-05 | 2005-10-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to treat chronic heart failure and/or elevated cholesterol levels |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3109023A (en) * | 1958-06-10 | 1963-10-29 | Hooker Chemical Corp | 2, 3, 6-trichloro-5-nitrobenzoic acid and salts thereof |
ZA824382B (en) * | 1981-07-07 | 1984-02-29 | Wyeth John & Brother Ltd | Anti-obesity agents |
GB8519154D0 (en) * | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
GB8714901D0 (en) * | 1986-07-23 | 1987-07-29 | Ici Plc | Amide derivatives |
GB8801306D0 (en) * | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
US5284971A (en) * | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
US5883294A (en) * | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
US6534676B2 (en) * | 2001-01-31 | 2003-03-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
ITRM20030363A1 (en) | 2003-07-24 | 2005-01-25 | Fernando Goglia | COMPOSITIONS INCLUDING 3THIODOTYRONIN AND PHARMACEUTICAL USE OF THEM. |
-
2008
- 2008-02-27 AU AU2008219585A patent/AU2008219585A1/en not_active Abandoned
- 2008-02-27 WO PCT/US2008/002680 patent/WO2008106213A1/en active Application Filing
- 2008-02-27 US US12/596,818 patent/US8399518B2/en not_active Expired - Fee Related
- 2008-02-27 MX MX2009009171A patent/MX2009009171A/en active IP Right Grant
- 2008-02-27 CA CA002679402A patent/CA2679402A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6951844B2 (en) * | 2001-12-07 | 2005-10-04 | Bristol Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
WO2005097102A2 (en) * | 2004-04-05 | 2005-10-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to treat chronic heart failure and/or elevated cholesterol levels |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012171065A1 (en) * | 2011-06-17 | 2012-12-20 | Esra Ogru | Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa). |
WO2024015764A1 (en) * | 2022-07-11 | 2024-01-18 | PriZm, LLC | 3,5-diiodothyropropionic acid compositions and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
US8399518B2 (en) | 2013-03-19 |
AU2008219585A1 (en) | 2008-09-04 |
CA2679402A1 (en) | 2008-09-04 |
US20100249235A1 (en) | 2010-09-30 |
MX2009009171A (en) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009257572B2 (en) | Low dose topiramate/phentermine composition and methods of use thereof | |
TWI230067B (en) | Pharmaceutical compositions for treating diabetic neuropathy or improving nerve conduction velocity or nerve blood flow comprising statin drug | |
TWI305726B (en) | Medicaments for diabetic complication and neuropathy | |
CN104220057B (en) | Pharmaceutical composition and method | |
AP1207A (en) | Combination therapy. | |
IL134271A (en) | Pharmaceutical compositions for altering lipids comprising nicotinic acid compounds and hmg-coa reductase inhibitors | |
EP2349280B1 (en) | Methods of treatment of hyperuricemia and associated disease states | |
US8399518B2 (en) | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome | |
RU2357731C2 (en) | Application of pirasole derivative for obtainment of medicine for prevention and treatment of dyslipidemia and diseases related to dyslipidemia and/or obesity | |
JPH08503451A (en) | Use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors as a modality for cancer treatment | |
US20190111064A1 (en) | Statin + vitamin d combination drug and method of use | |
Nayak et al. | The efficacy of antimalarials in systemic lupus erythematosus | |
AU2004218938B2 (en) | Combined use of a fibrate and orlistat for the treatment of obesity | |
AU2004298351A1 (en) | Use of stating for the treatment of metabolic syndrome | |
WO2006011495A1 (en) | Remedy for hypercholesterolemia and/or hypertriglyceridemia | |
RU2788450C2 (en) | Methods for weight loss therapy in patients with dominant depression | |
CN113133990A (en) | Ezetimibe-containing compound preparation and preparation method thereof | |
CN112370473A (en) | Statin composition and application thereof in preparation of medicine for treating hyperuricemia | |
US20090209613A1 (en) | Use of allymercaptocaptopril for treating or preventing obesity and obesity related diseases | |
JP2008273859A (en) | Antiarrhythmic comprising cibenzoline succinate as active ingredient for treating cardiac insufficiency patient having renal dysfunction | |
CN106310276A (en) | Pharmaceutical composition containing sugar and lipid reducing medicine and aspirin and folic acid | |
AU2016203699A1 (en) | Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity | |
AU2016202879A1 (en) | Drug combinations containing statins for treating cardiovascular diseases | |
AU2014202124A1 (en) | Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity | |
CN101057838A (en) | Medicine for preventing and/or curing hyperlipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08726252 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2679402 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008219585 Country of ref document: AU Ref document number: MX/A/2009/009171 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008219585 Country of ref document: AU Date of ref document: 20080227 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08726252 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12596818 Country of ref document: US |